Phase 2 N=34 Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Rates of Durable Engraftment — 17.9; 15.75; 13; 18.25 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=520 Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Primary: Number of Fertilized Oocytes (2 Pronuclei [PN]) — 7.0; 8.7; 9.2; 6.7 2PN oocytes
Phase 2 N=45 N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Penn Craving Scale — 24.0; 24.0; 21.1 units on a scale
Phase 2 N=72 0822GCC: Phase 2 Study of Efficacy and Safety of Apricoxib/Placebo With Docetaxel or Pemetrexed in Non-Small Cell Lung Cancer
Lung Cancer · Non Small Cell Lung Cancer
Primary: Progression Free Survival — 75; 97; 103; 98 days
Phase 2 N=18 Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes
Cowden's Disease · Hamartoma Syndrome, Multiple
Primary: Biochemical Changes in Benign and Malignant Tumor Tissues as Assessed by Immunohistochemistry.
Phase 2 N=528 Efficacy and Safety of Eslicarbazepine Acetate as Therapy in Subjects With Fibromyalgia
Fibromyalgia
Primary: Absolute Change From Baseline to Endpoint in Mean Pain — -1.0; -0.8; -1.2; -0.8 units on a scale
Phase 2 N=102 Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
Breast Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 28; 31 percentage of patients
Phase 2 N=1 Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer
Esophageal Cancer
Primary: Number of Adverse Events (AEs) Per Participant — 32 adverse events
Phase 2 N=112 Lapatinib in Combination With Vinorelbine
Cancer
Primary: Progression Free Survival (PFS) in the Randomized Phase — 6.2; 6.2 months
Phase 2 N=26 Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
Tumors
Primary: Maximum Tolerated Dose (MTD) of Single Agent Metronomic Oral Topotecan — 1.0 mg/day
Phase 2 N=50 Pharmacological Intervention Project (Fluoxetine)
Alcoholism · Depression
Primary: Alcohol Use Behaviors — 1.56; 1.73 standard drink (14 gr. alcohol) — p=.05
Phase 2 N=197 Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer
Breast Cancer
Primary: Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy — 65; 74; 65; 77 participants — p=0.641
Phase 2 N=215 Phase II Dose-ranging Study of APD421 in PONV
Postoperative Nausea and Vomiting
Primary: Post-operative Nausea or Vomiting — 37; 28; 20; 30 participants
Phase 2 N=92 A Study of the Bronchodilator Effect of Formoterol Fumarate Used in Combination With Mometasone Furoate Metered Dose Inhaler in Children With Persistent Asthma (P06476 AM2)
Asthma
Primary: Area Under the Curve From 0-12 Hours (AUC[0-12h]) of the Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) After a Single Dose of MF/F MDI With Spacer…
Phase 2 N=47 Efficacy Study of a Facemask Device to Treat Hypotension
Hypotension
Primary: Rise in Systolic Blood Pressure Over the First 10 Minutes of Use Compared to Baseline — 5.9; 12.9 mm Hg